Monoclonal antibody against CD45RB for the therapy of rejection and autoimmune diseases.
Rejection continues to be the single largest impediment to successful organ transplantation. Current therapy, which must be taken for a lifetime is nonspecific and has significant side effects including infection and cancer. There is a need to develop improved means of immunosuppression. The current goal of transplantation immunology is to induce a prolonged state of nonreactivity to the allograft but preserving an otherwise intact immune system (tolerance). We have recently reported that a monoclonal antibody against CD45RB is a potent immunosuppressive agent, and that it induces donor specific tolerance in the mouse. In this contribution we briefly review our understanding of the molecular basis for the activity of this therapy and update results in various transplant and autoimmune disease animal models. The clinical relevance and future development of this novel therapy is also discussed.
Zhong
R Z
RZ
Department of Surgery, University of Western Ontario, London Health Sciences Centre, Canada.
Lazarovits
A I
AI
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000628:therapy*; D006084:Graft Rejection / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D017493:Leukocyte Common Antigens / Q000276:immunology*
D000911:Antibodies, Monoclonal; D017493:Leukocyte Common Antigens